Miracell selected as one of the nation’s top 1000 innovative companies in the health and diagnostics sectors.
Smart Mcell 2 Successfully Localizes Advanced Bone Marrow and Blood Stem Cell Systems
Miracell, a stem cell specialist, has been selected by the government as one of the “National 1000 Innovative Companies.”
Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected for the third round of the “National 1,000 Innovative Companies,” a program announced by the Financial Services Commission based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. The “National 1,000 Innovative Companies” program, launched on July 30, 2020, was approved at the 12th meeting of the Central Emergency Economic Response Headquarters. The program, which involved nine ministries, including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries, selects representative innovative companies by industry and provides them with exceptional financial support to foster them as future core companies.
ⓒKorea Medical Association Newspaper
Starting with 32 companies in the first round, 247 were selected in the second round, and 321 companies were selected this time. The Financial Services Commission plans to select a total of 1,000 representative innovative companies by industry by 2022.
Miracell was selected as one of the “Health and Diagnostic Innovation Companies” in the health technology, medical device, and innovative pharmaceutical categories, based on selection criteria established by the Ministry of Health and Welfare. Launched in 2009 with the introduction of Harvard University’s cell extraction technology, Miracell successfully developed a “Minimally Manipulated Stem Cell Isolation and Amplification Source Technology” in 2017, and the Ministry of SMEs and Startups selected this technology for a small and medium-sized enterprise commercialization technology development project.
Based on this technology, Miracell successfully domestically developed and produced SMART M-CELL2, a replacement for the SmartPReP2 kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported globally.
Test results at Seoul National University Bundang Hospital showed that its performance was comparable to or even superior to that of SMART M-CELL2. SMART M-CELL2 is a device that extracts large quantities of automatically separated stem cells by centrifuging bone marrow blood extracted from the body. It is currently used in major hospitals both domestically and internationally.
Recognized as an innovative technology, SmartMcell2 is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be isolated and extracted in less than an hour, with a cell viability rate of 80-98%. Its automated system, which eliminates air contact and prevents cell mutation, is characterized by its closed, air-tight system. Equipped with special LEDs to enhance cell activity, SmartMcell2 has transitioned from analog to digital. It also features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices.
CEO Shin explained, “Stem cell treatment involves extracting bone marrow blood from the patient’s body, concentrating it through centrifugation, extracting a large quantity of stem cells, and then reinjecting them into the body. This process effectively improves bodily functions, as old cells regenerate into healthy ones.”
Source: Korean Medical Association Newspaper (http://www.doctorsnews.co.kr)